[1]王会敏,徐 克,穆 红.恩度联合顺铂局部治疗对非小细胞肺癌合并恶性胸腔积液肿瘤标志物的影响[J].医学信息,2021,34(16):106-108.[doi:10.3969/j.issn.1006-1959.2021.16.028]
　WANG Hui-min,XU Ke,MU Hong.Effect of Endo and Cisplatin Local Therapy on Tumor Markers of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Medical Information,2021,34(16):106-108.[doi:10.3969/j.issn.1006-1959.2021.16.028]
点击复制

恩度联合顺铂局部治疗对非小细胞肺癌合并恶性胸腔积液肿瘤标志物的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年16期
页码:
106-108
栏目:
论著
出版日期:
2021-08-15

文章信息/Info

Title:
Effect of Endo and Cisplatin Local Therapy on Tumor Markers of Non-small Cell Lung Cancer with Malignant Pleural Effusion
文章编号:
1006-1959（2021）16-0106-03
作者:
王会敏; 徐 克; 穆 红
（1.天津市第一中心医院检验科，天津 300190； 2.天津医科大学总医院/天津市肺癌转移与肿瘤微环境重点实验室，天津 300052）
Author(s):
WANG Hui-min; XU Ke; MU Hong
(1.Department of Laboratory Medicine,Tianjin First Central Hospital,Tianjin 300190,China; 2.General Hospital of Tianjin Medical University/Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment,Tianjin 300052,China)
关键词:
非小细胞肺癌; 恶性胸腔积液; 肿瘤标志物; 肺功能
Keywords:
Non-small cell lung cancer; Malignant pleural effusion; Tumor markers; Lung function
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2021.16.028
文献标志码:
A
摘要:
目的 分析恩度联合顺铂局部治疗对非小细胞肺癌（NSCLC）合并恶性胸腔积液（MPE）肿瘤标志物的影响。方法 回顾性分析2018年10月~2020年12月我院收治的NSCLC合并MPE化疗患者73例，根据治疗方案不同分为联合组36例和参照组37例。参照组给予顺铂治疗，联合组在参照组基础上联合恩度治疗，比较两组治疗疗效、肿瘤标志物指标水平、肺功能、生活质量及不良反应发生情况。结果 联合组治疗总有效率为80.56%，高于参照组的64.86%，差异有统计学意义（P＜0.05）；治疗后，联合组CEA、NSE、VEGF低于参照组，差异有统计学意义（P＜0.05）；联合组FEV1、FVC、FEV1/FVC水平、QOL评分高于参照组，差异有统计学意义（P＜0.05）；联合组不良反应发生率为11.11%，低于参照组的21.62%，差异有统计学意义（P＜0.05）。结论恩度联合顺铂局部治疗NSCLC合并MPE效果理想，可降低肿瘤标志物水平，减轻肺部损伤，改善患者生活质量，降低不良反应发生情况，具有应用安全性。
Abstract:
Objective To analyze the effect of Endo combined with cisplatin local treatment on tumor markers of non-small cell lung cancer(NSCLC) complicated with malignant pleural effusion(MPE).Methods A retrospective analysis of 73 NSCLC patients with MPE chemotherapy admitted to our hospital from October 2018 to December 2020 was divided into a combination group of 36 cases and a reference group of 37 cases according to different treatment options.The reference group was given cisplatin treatment, and the combination group was combined with Endo treatment on the basis of the reference group. The treatment efficacy, tumor marker index levels, lung function, quality of life, and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combined group was 80.56%, which was higher than 64.86% in the reference group,the difference was statistically significant (P<0.05);After treatment, CEA, NSE, and VEGF in the combined group were lower than those in the reference group,the difference was statistically significant(P<0.05);The FEV1, FVC, FEV1/FVC levels and QOL scores of the combined group were higher than those of the reference group,the difference was statistically significant (P<0.05);The incidence of adverse reactions in the combined group was 11.11%, which was lower than 21.62% in the reference group,the difference was statistically significant(P<0.05).Conclusion Endo combined with cisplatin is effective in the local treatment of NSCLC with malignant MPE.It can reduce the level of tumor markers, reduce lung damage, improve the quality of life of patients, reduce the occurrence of adverse reactions, and has application safety.

参考文献/References:

[1]方长清,丁春晓,刘小虎,等.结合恶性胸腔积液中脱落细胞探讨上皮细胞-间质转化与非小细胞肺癌的相关性[J].临床与实验病理学杂志,2020,36(1):43-47. [2]周菁,李索妮,焦咪,等.非小细胞肺癌胸腔积液中细胞角蛋白片段21-1与可溶性血管内皮生长因子受体-1的临床意义[J].中国临床研究,2020,33(12):1649-1652. [3]Kwok WC,Lam DCL,Chiang KY,et al.Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma[J].J Chemother,2020,32(8):429-436. [4]文雪梅.洛铂联合恩度胸腔灌注治疗非小细胞肺癌合并恶性胸腔积液的临床研究[J].国际呼吸杂志,2018,38(22):1694-1697. [5]刘丽莉,卢英杰,邵文龙.胸腔灌注化疗与胸腔循环热灌注化疗治疗非小细胞肺癌胸腔积液疗效比较[J].现代肿瘤医学,2019,27(11):1895-1899. [6]王园,田野,刘思洋,等.血管内皮生长因子及其受体在伴恶性胸腔积液非小细胞肺癌组织中的表达[J].中国医科大学学报,2016,45(5):441-444. [7]Xiong L,Lou Y,Bai H,et al.Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients[J].J Int Med Res,2020,48(4):300060519887275. [8]林凤华,苏伟平,金润女.贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液临床研究[J].临床军医杂志,2016,44(7):698-700. [9]郎然,金建军,张彭辉,等.白蛋白结合型紫杉醇联合顺铂对非小细胞肺癌引起的恶性胸腔积液的疗效[J].广东医学,2018,39(15):2369-2372,2376. [10]李志虎,杨燕,张莲兴.吉西他滨或培美曲塞静脉化疗联合顺铂胸腔灌注在非小细胞肺癌合并恶性胸腔积液中的应用研究[J].癌症进展,2018,16(3):342-344,374. [11]肖佳,翁洁,文芳,等.顺铂、香菇多糖及贝伐单抗灌注治疗初治非小细胞肺癌恶性胸腔积液的临床观察[J].现代诊断与治疗,2016,27(12):2202-2204. [12]董婷,崔丽花,毛露凤,等.百合固金汤加减联合顺铂胸腔内注射治疗非小细胞肺癌合并恶性胸腔积液临床研究[J].新中医,2020,52(18):40-43.

相似文献/References:

[1]李雪芹,王存德,龚 泉,等.鸦胆子油乳注射液配合恩度治疗恶性胸腔积液的临床分析[J].医学信息,2018,31(03):13.[doi:10.3969/j.issn.1006-1959.2018.03.005]
　LI Xue-qin,WANG Cun-de,GONG Quan,et al.Clinical Analysis of Brucea Javanica Oil Emulsion Injection Combined with Endor in the Treatment of Malignant Pleural Effusion[J].Medical Information,2018,31(16):13.[doi:10.3969/j.issn.1006-1959.2018.03.005]
[2]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(16):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[3]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(16):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[4]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(16):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[5]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(16):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[6]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(16):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(16):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(16):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[9]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(16):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[10]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(16):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[11]罗 超,葛明建.非小细胞肺癌干性胸膜转移的研究现状[J].医学信息,2021,34(03):31.[doi:10.3969/j.issn.1006-1959.2021.03.010]
　LUO Chao,GE Ming-jian.Research Status of Stem Pleural Metastasis of Non-small Cell Lung Cancer[J].Medical Information,2021,34(16):31.[doi:10.3969/j.issn.1006-1959.2021.03.010]
[12]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
　SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Medical Information,2021,34(16):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]

更新日期/Last Update: 1900-01-01